ProciseDx Inc. announces that it has been granted de novo FDA clearance for the therapeutic drug monitoring (TDM).
Anixa Biosciences, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa’s novel ovarian cancer vaccine technology.
Lokavant , the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region.
Cybin Inc. today announced the completion of dosing of the final cohort in its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog program in development for the potential treatment of major depressive disorder (“MDD”).
Capsida Biotherapeutics Inc. (“Capsida”) and Kate Therapeutics (“KateTx”) today announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.
Las experiencias místicas y religiosas han sido un componente intrínseco de la historia de la humanidad desde tiempos inmemoriales. Muchos individuos afirman haber tenido encuentros con lo divino, trascendiendo la realidad cotidiana. Aunque estas experiencias a menudo se han interpreta …
El origen antropológico de las experiencias místicas y religiosas Read More »
Sphere Fluidics announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world leading end-to-end antibody partner, providing integrated services across antibody discovery, engineering, and production, to expand its cell line development capabilities.
Copenhagen, Denmark – FluoGuide A/S, a pioneer in the cutting-edge field of precision cancer surgery, is pleased to announce its lead asset FG001 has received Orphan Drug Designation from the U. S. Food and Drug Administration as an optical imaging agent for the visualization of malignant tissue during surgery for high-grade glioma.
FluoGuide receives FDA Orphan Drug Designation for FG001 in High-Grade Glioma Read More »
Orexo AB, Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on 26 October 2023 at 15:00 CEST at Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden.
Notice of Extraordinary General Meeting in Orexo AB (publ) Read More »
Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E.coli developed by Janssen, currently in Phase 3.
